伊特卡賽肽（商品名為Parsabiv^TM）是安進公司開發(fā)的新型二代擬鈣劑，主要用于治療慢性腎病繼發(fā)性甲狀旁腺機能亢進。伊特卡賽肽通過直接與鈣感應受體結合來降低血鈣濃度，還可以降低甲狀旁腺素的水平。歐盟于2016年11月批準注射用伊特卡賽肽用于慢性腎病繼發(fā)性甲狀旁腺機能亢進的透析患者。介紹該藥的藥理作用、藥動學、臨床試驗及不良反應研究概況。

Etelcalcetide (Parsabiv^TM) is a second generation calcimimetic agent newly developed by Amgen, mainly used for the treatment of secondary hyperparathyroidism. Etelcalcetide not only decreases calcium concentration by directly binding with the calcium sensing receptor, but also reduces the parathyroid hormone level. The European Union has approved for chronic kidney disease patients with secondary hyperparathyroidism in dialysis with Etelcalcetide injection. This paper summarized the pharmacological effects, pharmacokinetics, clinical trials, and adverse reaction of Etelcalcetide.